Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.

Ann Rheum Dis · 2022 · PMC9120383 · PMID 35210262

Europe PMC DOI

hedged sentence

0.0632

closest p · 1.3× alpha

0.0632

boldest claim

The sentences

showed a trendp=0.0632so close (0.05 < p ≤ 0.1)

This was partly confirmed in the PS-adjusted Cox persistence analysis that showed a trend (p=0.0632) towards an interaction between the factor skin involvement and the treatment cohort, with longer persistence on ustekinumab in patients with baseline BSA >10% (HR: 0.41; 95% CI 0.19; 0.89).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.